InnoCan Pharma Corporation (CSE:INNO)
2.170
-0.020 (-0.91%)
Aug 28, 2026, 3:44 PM EST
InnoCan Pharma Revenue
InnoCan Pharma had revenue of $6.47M USD in the quarter ending March 31, 2026, a decrease of -17.07%. This brings the company's revenue in the last twelve months to $25.28M, down -17.02% year-over-year. In the year 2025, InnoCan Pharma had annual revenue of $26.61M, down -9.60%.
Revenue (ttm)
$25.28M
Revenue Growth
-17.02%
P/S Ratio
0.28
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.76M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.61M | -2.83M | -9.60% |
| Dec 31, 2024 | 29.44M | 15.78M | 115.55% |
| Dec 31, 2023 | 13.66M | 11.10M | 433.69% |
| Dec 31, 2022 | 2.56M | 2.36M | 1,205.61% |
| Dec 31, 2021 | 196.00K | 188.00K | 2,350.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| George Weston | 65.69B |
| Loblaw Companies | 65.07B |
| Metro | 22.48B |
| Dollarama | 7.58B |
| Big Rock Brewery | 49.00M |
| Green Rise Foods | 32.39M |
| Diamond Estates Wines & Spirits | 28.68M |
| Eshbal Functional Food | 21.49M |
InnoCan Pharma News
- 3 months ago - InnoCan Pharma Registration statement: Q1 2026 - Filings
- 3 months ago - InnoCan Pharma Registration statement: Q1 2026 - Filings
- 3 months ago - InnoCan Pharma Earnings release: Q1 2026 - Filings
- 5 months ago - InnoCan Pharma Earnings release: Q4 2025 - Filings
- 5 months ago - InnoCan Pharma Registration statement: Q4 2025 - Filings
- 5 months ago - InnoCan Pharma Registration statement: Q4 2025 - Filings
- 5 months ago - Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M - PRNewsWire
- 6 months ago - FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time - PRNewsWire